Stericycle, Inc.

NasdaqGS:SRCL Rapport sur les actions

Capitalisation boursière : US$5.8b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Stericycle Résultats passés

Passé contrôle des critères 2/6

Stericycle a connu une croissance annuelle moyenne de ses bénéfices de 71.3%, tandis que le secteur Commercial Services a vu ses bénéfices augmenter de en hausse à 9.7% par an. Les revenus ont augmenté de en baisse à un taux moyen de 3.9% par an. Le rendement des capitaux propres de Stericycle est 0.8% et ses marges nettes sont de 0.8%.

Informations clés

71.30%

Taux de croissance des bénéfices

71.44%

Taux de croissance du BPA

Commercial Services Croissance de l'industrie8.53%
Taux de croissance des recettes-3.86%
Rendement des fonds propres0.79%
Marge nette0.77%
Dernière mise à jour des bénéfices30 Sep 2024

Mises à jour récentes des performances passées

Recent updates

Seeking Alpha • Jun 04

Waste Management's Big Move Is A Win For Stericycle

Summary Waste Management announces the acquisition of Stericycle in a $7.15 billion all-cash deal, causing Stericycle shares to spike and Waste Management shares to drop. Stericycle shareholders benefit from the premium offer and can exit their position, while Waste Management's success depends on the realization of synergies and the impact on leverage. Waste Management aims to expand its environmental service offerings and gain access to Stericycle's regulated waste and compliance services, as well as its secure information destruction services. Read the full article on Seeking Alpha
Seeking Alpha • May 22

Stericycle: Watch Potential Revenue Recovery And Margin Improvement

Summary SRCL's Q1 2024 operating margins beat expectations, and the company's EBITDA margin is expected to improve significantly for full-year 2024. I anticipate that Stericycle's Secure Information Destruction segment can realize a turnaround due to a more favorable base for YoY comparison in 2H and the introduction of a subscription service. My Buy rating for SRCL stays intact following an assessment of its outlook and valuations. Read the full article on Seeking Alpha
Seeking Alpha • Mar 03

Stericycle: Earnings Beat And Above-Expectations Guidance Reinforce My Buy Rating

Summary Stericycle's normalized EPS grew by +26% QoQ in Q4 2023, and this translated into a +14% bottom line beat. The company is anticipating that its earnings will expand strongly by +24% in this new fiscal year, which is better than what Wall Street had anticipated earlier. I stick to a Buy investment rating for Stericycle stock, as I have greater confidence in SRCL's long-term prospects after reviewing its Q4 results and 2024 guidance. Read the full article on Seeking Alpha
Seeking Alpha • Aug 30

Stericycle: Muted Outlook, Fair Valuations

Summary Stericycle's revenue outlook is murky, the recovery for the secure information destruction business is still in progress, but the regulated waste and compliance segment might be affected by staffing shortages. SRCL should still record lower earnings for FY 2022 vis-a-vis FY 2021 despite delivering an EPS beat in Q2, due to higher operating and interest expenses. I continue to assign a Hold rating to Stericycle, as its valuations are reasonably fair and aligned with its full-year outlook. Elevator Pitch I rate Stericycle, Inc.'s (SRCL) stock as a Hold. I evaluated SRCL's pace of recovery from the pandemic and its capital allocation plans in an earlier October 22, 2021 article for the stock. I focus on the near-term expectations for Stericycle in this update. My analysis leads me to the conclusion that the consensus earnings forecasts implying a mid-single digit percentage decline for SRCL in FY 2022 are realistic, and Stericycle's current valuations seem to be fair taking into account the full-year outlook. As such, I maintain a Hold rating for SRCL. Revisions To Consensus Estimates The recent changes to the sell-side's consensus bottom line forecasts for Stericycle provide an indication of what the market expects of SRCL's future performance. The consensus Q3 2022 normalized earnings per share or EPS for SRCL has been revised upwards by a substantial +11% in the past one month. It is reasonable to assume that the Wall Street analysts had raised their third-quarter bottom line projections for the company in response to Stericycle's +9% EPS beat for Q2 2022. It is worthy of note that SRCL has had earnings misses for the prior four quarters between Q2 2021 and Q1 2022. But the full-year fiscal 2022 consensus numbers tell a different story. In the last one month, the market's consensus FY 2022 normalized EPS estimate ($2.06) for Stericycle has in fact been reduced slightly by -0.5%, notwithstanding SRCL's second-quarter earnings beat. Moreover, four of the eight analysts covering SRCL's shares actually lowered their EPS estimates for the company in the past month. The analysts' less than favorable view of Stericycle's full-year FY 2022 outlook might be linked to the company's most recently updated management guidance. At its Q2 2022 earnings call in early-August 2022, SRCL increased the mid-point of its FY 2022 revenue growth guidance from +4% to +5%, but it lowered the mid-point of its full-year EPS guidance from $2.15 to $2.075 (implying a -5% decline as compared to 2021 EPS of $2.19). In the rest of the article, I will assess the growth prospects of its two key business segment and the company's overall profitability. This will help to explain why company management and analysts are of the opinion that Stericycle's bottom line for FY 2022 will still contract despite above-expectations Q2 2022 earnings. Secure Information Destruction Business Performed Well in Q2 Organic revenue for Stericycle's secure information destruction business, adjusted to exclude inorganic transactions and foreign exchange effects, expanded by an impressive +12.2% YoY for the second quarter of 2022. The expectations for SRCL's secure information destruction segment weren't high, as this business faces structural challenges relating to reduced paper usage in an increasingly digitalized world. However, the company's business secure information destruction business has witnessed a meaningful recovery in Q2 2022, as pandemic restrictions are eased and an increasing number of workers return to offices. More critically, the current recovery for the secure information destruction segment still has legs to run. Stericycle highlighted at its second-quarter results briefing that "I don't think the industry has settled yet in terms of everybody being back to what is the new normal." In other words, SRCL is implying that there could be a further acceleration in the pace of people going back to offices in time to come, and this will be positive for the secure information destruction business' near-term outlook. Disappointing Performance For Regulated Waste And Compliance Services Segment In contrast with the double-digit top line growth for the secure information destruction segment in the recent quarter, Stericycle's other segment, the regulated waste and compliance services business disappointed investors with its Q2 2022 results. Specifically, the regulated waste and compliance services segment saw a very modest +1.8% YoY increase in its second-quarter organic revenue. Notably, SRCL mentioned at its Q2 2022 earnings briefing that "most of the growth" for the company's regulated waste and compliance services segment for the most recent quarter "was due to pricing." This suggests that volumes for this business was probably flattish on a YoY basis in the second quarter of this year. There are two key factors that explain why the regulated waste and compliance services business' volumes haven't grown in a meaningful way in the recent quarter. Firstly, there was a decline in COVID-19 testing and vaccinations in Q2, as COVID-19 transitions gradually into an endemic state. Secondly, the labor crunch has also affected the healthcare industry, which means that it is tough for the number of elective surgeries to return to similar levels seen before the pandemic anytime soon. Future Profitability Hurt By Operating Cost Pressures And Higher Interest Rates As discussed in an earlier section of the article, Stericycle cut its full-year FY 2022 bottom line guidance after it reported its Q2 2022 earnings. SRCL attributed this change to "higher cash operating and interest expenses" at its most recent quarterly investor call.
Seeking Alpha • Aug 04

Stericycle Q2 2022 Earnings Preview

Stericycle (NASDAQ:SRCL) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is $0.44 (-34.3% Y/Y) and the consensus Revenue Estimate is $678.27M (+0.8% Y/Y). Over the last 2 years, SRCL has beaten EPS estimates 38% of the time and has beaten revenue estimates 50% of the time. Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downward. Revenue estimates have seen 2 upward revisions and 1 downward.
Seeking Alpha • Jun 03

Stericycle: The Risks Outweigh The Reward

Stericycle seems to be in a continued state of decline, even though the pandemic is largely over. If shares were cheap enough, the company might be worth the risk, but that isn't the case either. Add in regulatory risks moving forward, and it's not worth the risk playing this name right now.
Seeking Alpha • Oct 22

Stericycle: A Neutral View

I am negative on SRCL's recovery prospects in the short term, as there has been a delay in the return of workers back to office. But I have a favorable opinion of Stericycle's capital allocation initiatives in relation to debt reduction and business or asset sales. Stericycle currently trades at consensus forward FY 2021 and FY 2022 normalized P/E multiples of 26.9 times and 25.2 times, respectively, and this seems expensive.
Seeking Alpha • Aug 08

Stericycle: A Successful Turnaround Is Likely

Revenues declined in 2018, 2019, and 2020 as the company is divesting some businesses. Long-term debt has dramatically declined in recent quarters. The company is highly profitable. Shares are down by ~55% from all-time highs in 2015. This is a turnaround play worth the risk at this price.

Ventilation des recettes et des dépenses

Comment Stericycle gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.

Historique des gains et des recettes

NasdaqGS:SRCL Recettes, dépenses et bénéfices (USD Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Sep 242,627206920
30 Jun 242,632366950
31 Mar 242,640-196960
31 Dec 232,659-217070
30 Sep 232,678-46980
30 Jun 232,715227050
31 Mar 232,725816980
31 Dec 222,705567070
30 Sep 222,69277070
30 Jun 222,650-877000
31 Mar 222,643-686860
31 Dec 212,647-287160
30 Sep 212,646386340
30 Jun 212,633236310
31 Mar 212,559-116200
31 Dec 202,676-577300
30 Sep 202,820-3256770
30 Jun 203,016-3036980
31 Mar 203,264-3297530
31 Dec 193,309-3478540
30 Sep 193,362-4468100
30 Jun 193,384-3697840
31 Mar 193,421-3128160
31 Dec 183,486-2531,0430
30 Sep 183,5211488260
30 Jun 183,5491668120
31 Mar 183,583-98140
31 Dec 173,581238400
30 Sep 173,599-479870
30 Jun 173,607-211,0250
31 Mar 173,5811659650
31 Dec 163,5621787770
30 Sep 163,5442367150
30 Jun 163,3732446610
31 Mar 163,1972956050
31 Dec 152,9862575940
30 Sep 152,7752695060
30 Jun 152,7242824950
31 Mar 152,6492764820
31 Dec 142,5563264340
30 Sep 142,4473224280
30 Jun 142,3133204080
31 Mar 142,1993163840
31 Dec 132,1433113800

Des revenus de qualité: SRCL a un important ponctuel perte de $78.4M impactant ses 12 derniers mois de résultats financiers à 30th September, 2024.

Augmentation de la marge bénéficiaire: SRCL est devenu rentable dans le passé.

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Tendance des revenus: SRCL est devenue rentable au cours des 5 dernières années, augmentant ses bénéfices de 71.3% par an.

Accélération de la croissance: SRCL est devenu rentable au cours de l'année dernière, ce qui rend le taux de croissance des bénéfices difficile à comparer à sa moyenne sur 5 ans.

Bénéfices par rapport au secteur d'activité: SRCL est devenue rentable au cours de l'année dernière, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Commercial Services ( 7.2% ).

Rendement des fonds propres

ROE élevé: Le retour sur capitaux propres de SRCL ( 0.8% ) est considéré comme faible.

Rendement des actifs

Rendement des capitaux employés

Découvrir des entreprises performantes dans le passé

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2024/11/04 12:53
Cours de l'action en fin de journée2024/11/01 00:00
Les revenus2024/09/30
Revenus annuels2023/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Stericycle, Inc. est couverte par 21 analystes. 7 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Gary BisbeeBarclays
Alexander ParisBarrington Research Associates, Inc.
Kevin SteinkeBarrington Research Associates, Inc.